Login to Your Account

Millennium Starts Pivotal Trial of Aurora Kinase Drug in PTCL

By Catherine Shaffer
Staff Writer

Wednesday, March 7, 2012

Millennium, a unit of Takeda Pharmaceutical Co. Ltd., may soon be able to add peripheral T-cell lymphoma (PTCL) to its list of cancers that can be treated with its investigational Aurora A kinase inhibitor, MLN8237 (alisertib).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription